Treatments compared for pediatric-onset multiple sclerosis

Treatments compared for pediatric-onset multiple sclerosis

More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.

Patrick Vermersch, M.D., Ph.D., from the Centre Hospitalier Universitaire de Lille in France, and colleagues conducted an active-controlled, open-label randomized clinical trial involving patients with POMS aged 10 to <18 years. A total of 150 patients with POMS were randomly assigned to DMF or IFNβ-1a (78 and 72 individuals, respectively).

The researchers found that among the 103 trial completers, the proportion of patients with no N or NE T2 hyperintense lesions at week 96 was 16.1 and 4.9 percent for DMF and IFNβ-1a, respectively; in a sensitivity analysis among the intention-to-treat population, the proportions were 12.8 and 2.8 percent, respectively. The estimated proportion of patients who remained relapse-free was 66.2 and 52.3 percent for DMF and IFNβ-1a, respectively, at week 96. The adjusted annualized relapse rate was 0.24 and 0.53 for DMF and IFNβ-1a, respectively, at week 96; the rate ratio was 0.46 for DMF versus IFNβ-1a.

"The CONNECT randomized clinical trial found that DMF led to meaningful improvements in radiological and clinical outcomes in patients with POMS, with a positive benefit-risk balance," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Biogen, which manufactures and funded the trial.

More information: Patrick Vermersch et al, Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis, JAMA Network Open (2022). DOI: 10.1001/jamanetworkopen.2022.30439

Omar Abdel-Mannan et al, Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial, JAMA Network Open (2022). DOI: 10.1001/jamanetworkopen.2022.30451

Journal information: JAMA Network Open

Copyright © 2022 HealthDay. All rights reserved.

Citation: Treatments compared for pediatric-onset multiple sclerosis (2022, October 6) retrieved 21 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Transdermal CBD no better than placebo for drug-resistant focal epilepsy


Feedback to editors